<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395522</url>
  </required_header>
  <id_info>
    <org_study_id>MT-06</org_study_id>
    <nct_id>NCT03395522</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH</brief_title>
  <acronym>MT-06</acronym>
  <official_title>One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-tate Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medi-Tate Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medi-Tate Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study.

      Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year
      3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Study Objective:

      The study's primary objective is to assess the efficacy of the Medi-Tate iTind in subjects
      with symptomatic BPH by reduction of IPSS) (International Prostate Symptoms Score) score.

      Secondary Study Objectives:

        -  To further evaluate the efficacy of Medi-Tate iTind as determined by increase of maximal
           urinary peak flow, satisfaction from the device and procedures, sex performance
           capabilities and ejaculation.

        -  Safety will be assessed by the rate of complications attributed to the Medi-Tate iTind
           and its implantation/retrieval procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>device group only</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IPSS (International Prostate Symptoms Score) Responders Rate</measure>
    <time_frame>at Month 6 Visit</time_frame>
    <description>the Proportion (%) of Total IPSS Responders (3 points) Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total IPSS (International Prostate Symptoms Score) Score at</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total IPSS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IPSS(International Prostate Symptoms Score) Urinary Symptoms Score</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total IPSS Urinary Symptoms Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total SHIM (Sexual Health Inventory for Men ) Score</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total SHIM Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ISI (Incontinence Severity Index ) Score</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total ISI Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total EJ-MSHQ ( Ejaculation- Male Sexual Health questionnaire) Score</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total EJ-MSHQ Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Flow</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total Flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total residual urine</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total residual urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Satisfaction Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in Total Satisfaction Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS QoL (Quality Of Life) score</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline to Month 6 in IPSS QoL score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery Success Rate</measure>
    <time_frame>1 month</time_frame>
    <description>Quality of Recovery Success Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITind device implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTind</intervention_name>
    <description>device implanted for 5-7 days</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject signed informed consent prior to the performance of any study procedures.

          -  Male with symptomatic BPH: IPSS symptom severity score ≥ 10

          -  Peak urinary flow of &lt; 12 ml/sec at flowmetry with minimum voided volume of at least
             120 cc.

          -  Prostate volume 25 ml to 80 ml (as assessed by TRUS)

          -  Subject that is able to complete the study protocol

          -  Normal Urinalysis and urine culture.

        Exclusion Criteria:

          -  Previous prostate surgery

          -  Prostate cancer

          -  Urethral stricture

          -  Bladder stones

          -  An active urinary tract infection.

          -  Obstructing median lobe demonstrated by IPP grade 3 (&gt;1 cm) as assessed by TRUS.

          -  Neurological conditions potentially affecting voiding function.

          -  A post void residual (PVR) volume &gt; 250 ml measured by ultrasound

          -  Previous diagnosis or treatment for Over Active Bladder

          -  Acute Urinary Retention

          -  Any anatomical or physiological condition that in the opinion of the investigator
             likely to impede successful completion of the study

        Intra-Operation Exclusion:

        • Obstructing median lobe or any other anatomical or physiological pathology that can
        interfere the device implantation as assessed by cystoscopy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male with symptomatic BPH</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Porpiglia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Orbessano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lihi Liviatan</last_name>
    <phone>972543114797</phone>
    <email>lihi@medi-tate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sydney Adventist Hospital Clinical School of the University of Sydney</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry Woo</last_name>
    </contact>
    <contact_backup>
      <last_name>Thijs Wervelman</last_name>
      <email>thijs.wervelman@avaniaclinical.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AKH Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Pozo</last_name>
      <email>carmen.pozosalido@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Veronika Auner-Moser</last_name>
      <phone>+43-1-40400-54780</phone>
      <email>veronika.auner-moser@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Center University De Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégoire ROBERT, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Meric BEN BOUJEMA</last_name>
      <email>meric.ben-boujema@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Barry Delongchamps, Prof</last_name>
    </contact>
    <contact_backup>
      <last_name>Gwenaelle PONTDEME</last_name>
      <email>gwenaelle.pontdeme2@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé des Côtes d'Armor</name>
      <address>
        <city>Plérin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Della Negra</last_name>
      <email>negra.emmanuel@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Becker</last_name>
      <email>Andreas.Becker@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Anke Strebel</last_name>
      <phone>+4969/6301-84778</phone>
      <email>Anke.Strebel@kgu.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical center - University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schönthaler</last_name>
      <email>martin.schoenthaler@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Oksana Ermantraut</last_name>
      <phone>+4976127077102</phone>
      <email>oksana.ermantraut@uniklinik-freiburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten Bach, MD</last_name>
      <email>an.wahlers@asklepios.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU di Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>San'Andrea Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Orbessano</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica CEMTRO Ventisquero la Condesa</name>
      <address>
        <city>Madrid</city>
        <zip>42 28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spital Thurgau AG</name>
      <address>
        <city>Frauenfeld</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Rohrmann</last_name>
      <email>karl.rohrmann@stgag.ch</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Keller</last_name>
      <email>alexandra.keller@stgag.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Abt</last_name>
      <email>Dominik.Abt@kssg.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

